Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
1. HRMY received FDA's Refusal to File for pitolisant in IH. 2. 2025 revenue guidance of $820-$860 million remains intact. 3. Phase 3 trial for Pitolisant HD is planned for Q4 2025. 4. Wakix sales rose, with net revenue increasing to $201 million. 5. Analyst maintains 'Buy' but lowers price target from $52 to $50.